U.S. patent number 9,392,229 [Application Number 13/467,851] was granted by the patent office on 2016-07-12 for iontophoresis methods.
This patent grant is currently assigned to TUSKER MEDICAL, INC.. The grantee listed for this patent is Kate Hames, Greg Liu, John H. Morriss. Invention is credited to Kate Hames, Greg Liu, John H. Morriss.
United States Patent |
9,392,229 |
Morriss , et al. |
July 12, 2016 |
Iontophoresis methods
Abstract
A method of anesthetizing a tympanic membrane of an ear of a
patient using iontophoresis is disclosed. The method involves
delivering an anesthetizing drug solution to an ear canal of the
patient's ear, wherein the drug solution includes an anesthetic and
a buffer, and wherein the drug solution has a pH in the range of
about 6.5 to about 7.5; and applying an amount of current to the
drug solution, wherein the amount of applied current is increased
at a rate of less than about 0.5 milliamp per minute until a
maximum current is achieved.
Inventors: |
Morriss; John H. (San
Francisco, CA), Liu; Greg (Sunnyvale, CA), Hames;
Kate (San Francisco, CA) |
Applicant: |
Name |
City |
State |
Country |
Type |
Morriss; John H.
Liu; Greg
Hames; Kate |
San Francisco
Sunnyvale
San Francisco |
CA
CA
CA |
US
US
US |
|
|
Assignee: |
TUSKER MEDICAL, INC. (Menlo
Park, CA)
|
Family
ID: |
40789478 |
Appl.
No.: |
13/467,851 |
Filed: |
May 9, 2012 |
Prior Publication Data
|
|
|
|
Document
Identifier |
Publication Date |
|
US 20120220923 A1 |
Aug 30, 2012 |
|
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
11962063 |
Dec 20, 2007 |
8192420 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
H04N
21/6581 (20130101); A61N 1/325 (20130101); A61F
11/00 (20130101); H04N 21/8352 (20130101); A61N
1/306 (20130101); H04N 7/17318 (20130101); A61N
1/303 (20130101); H04N 21/4722 (20130101); A61K
33/00 (20130101); H04N 21/858 (20130101); A61M
19/00 (20130101); A61K 31/167 (20130101); A61K
9/0009 (20130101); A61N 1/36021 (20130101); A61M
2210/0662 (20130101) |
Current International
Class: |
A61N
1/30 (20060101); H04N 7/173 (20110101); H04N
21/858 (20110101); H04N 21/8352 (20110101); A61F
11/00 (20060101); H04N 21/4722 (20110101); H04N
21/658 (20110101) |
Field of
Search: |
;604/20-22,500,501,512 |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
86105171 |
|
Mar 1987 |
|
CN |
|
19618585 |
|
Nov 1997 |
|
DE |
|
0214527 |
|
Jan 1991 |
|
EP |
|
2526656 |
|
Nov 1983 |
|
FR |
|
WO 2006/119512 |
|
Nov 2006 |
|
WO |
|
WO 2008/030485 |
|
Mar 2008 |
|
WO |
|
WO 2008/036368 |
|
Mar 2008 |
|
WO |
|
WO 2009/010788 |
|
Jan 2009 |
|
WO |
|
Other References
US. Appl. No. 61/085,360, filed Jul. 31, 2008. cited by applicant
.
U.S. Appl. No. 11/749,729, filed May 16, 2007. cited by applicant
.
U.S. Appl. No. 11/749,733, filed May 16, 2007. cited by applicant
.
U.S. Appl. No. 11/962,063, filed Dec. 20, 2007. cited by applicant
.
U.S. Appl. No. 11/962,073, filed Dec. 20, 2007. cited by applicant
.
Comeau, M. et al `Local Anesthesia of the Ear by Iontophresis`
(1973) Arch Otolaryngol. vol. 98 pp. 114-120. cited by applicant
.
Comeau, M. et al `Anesthesia of the Human Tympanic Membrane by
Iontophoresis of a Local Anesthetic 11978` The Larynogoscope vol.
88 pp. 277-285. cited by applicant .
Echols, D.F. et al `Anesthesia of the Ear by Iontophoresis of
Lidocaine` (1975) Arch Otolaryngol. vol. 101, pp. 418-421. cited by
applicant .
Epley, J.M. `Modified Technique of Iontophoretic Anesthesia for
Myringotomy in Children` (1977) Arch Otolaryngol. vol. 103 pp.
358-360. cited by applicant .
Hasegawa, M. et al `Iontophorectic Anaesthesia of the Tympanic
Membrane` (1978) Clinical Otolaryngoloy. vol. 3 pp. 63-66. cited by
applicant .
Micromedics Innovative Surgical Products [retrieved on Jul. 15,
2010] Retrieved from the Internet <URL:
http://www.micromedics-usa.com/products/otology/micromedicstubes.htm.
7 pages. cited by applicant .
plenum' Compact Oxford English Dictionary
<http://oxforddictionaries.com/definition/english/plenum>.
cited by applicant .
plenum' Merriam-Webster's Online Dictionary , 11th Edition.
<http://www.merriam-webster.com/dictionary/plenum>. cited by
applicant .
Ramsden, R.T. et al `Anaesthesia of the Typanic Membrane Using
Iontophoresis` (1977) The Journal of Layngology and Otology. vol.
56, No. 9. pp. 779-785. cited by applicant .
International Search Report dated Sep. 3, 2008 re:
PCT/US2008/60779. cited by applicant .
International Search Report dated Nov. 6, 2009 re: PCT/2009/052395.
cited by applicant .
International Search Report dated Jun. 30, 2010 re:
PCT/US2009/069388. cited by applicant .
International Search Report dated Aug. 27, 2010 re:
PCT/US2010/042128. cited by applicant .
International Search Report dated Feb. 17, 2011 re:
PCT/US2010/058718. cited by applicant .
Medtronic XOMED, "Activent.RTM. Antimicrobial Ventilation Tubes,"
Rev. 1.1, pp. 1-4, 2002, Jacksonville, Fl. cited by
applicant.
|
Primary Examiner: Hayman; Imani
Parent Case Text
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a divisional of and claims priority to U.S.
patent application Ser No. 11/962,063, filed Dec. 20, 2007,
entitled "Iontophoresis Methods," now U.S. Pat. No. 8,192,420.
Claims
What is claimed is:
1. An iontophoresis system for anesthetizing a tympanic membrane of
an ear of a patient, the system comprising: (a) an anesthetizing
drug solution for applying to the tympanic membrane, the
anesthetizing drug solution comprising an anesthetic and a buffer,
wherein the buffer is configured to raise the pH of the drug
solution to an increased pH in the range of 6.8 to 7.2, and wherein
the anesthetizing drug solution further comprises: i. a percent
weight of Lidocaine greater than 2% by weight, wherein the percent
weight of Lidocaine is proportional to the increased pH of the
anesthetizing drug solution; and ii. approximately 0.5% to 1.0% of
sodium bicarbonate by weight; (b) a current source; (c) an
electrode configured for placement within the ear of the patient in
contact with the drug solution; and (d) a controller coupled with
the current source, the controller programmed to increase an amount
of current applied through the electrode to the drug solution at a
rate of less than 0.5 milliamp per minute until a maximum current
of less than 1.0 milliamp is achieved.
2. The system of claim 1, wherein the anesthetizing drug solution
comprises an anesthetic, and a vasoconstrictor.
3. The system of claim 2, wherein the vasoconstrictor comprises
epinephrine.
4. The system of claim 1, wherein the controller is programmed to
increase the amount of current applied to the drug solution at a
rate of 0.2 milliamp per minute until a maximum current of 0.8
milliamp is achieved.
5. The system of claim 1, wherein the current source comprises at
least one ear electrode configured for placement in an ear canal of
the patient.
6. The system of claim 5, wherein the current source comprises two
ear electrodes configured for placement in two ear canals of the
patient, thus allowing for approximately simultaneous application
of current to anesthetizing drug solution disposed in the two ear
canals.
7. The system of claim 1, wherein the current applied to the drug
solution is direct current.
8. The system of claim 1, wherein the maximum current is at least
0.5 milliamp.
9. An iontophoresis system for anesthetizing a tympanic membrane of
an ear of a patient, the system comprising: (a) an anesthetizing
drug solution for applying to the tympanic membrane, the
anesthetizing drug solution comprising an anesthetic and a buffer,
wherein the buffer is configured to raise the pH of the drug
solution to an increased pH in the range of 6.8 to 7.2, and wherein
the anesthetizing drug solution further comprises: i. a percent
weight of Lidocaine, wherein the percent weight of Lidocaine is at
least 3.5%; and ii. approximately 0.5% to 1.0% of sodium
bicarbonate by weight; (b) a current source; (c) an electrode
configured for placement within the ear of the patient in contact
with the drug solution; and (d) a controller coupled with the
current source, the controller programmed to increase an amount of
current applied through the electrode to the drug solution at a
rate of less than 0.5 milliamp per minute until a maximum current
of less than 1.0 milliamp is achieved.
Description
BACKGROUND OF THE INVENTION
The present invention is related to iontophoretic drug delivery
methods and systems. In particular, the present invention is
related to novel and advantageous iontophoretic drug delivery
methods and systems for anesthetizing ear tissue.
Iontophoresis is a method for delivering a drug across a biological
membrane, such as the skin or, in the case of certain ear surgery
procedures, the tympanic membrane (TM). By applying low-level
electrical current to a similarly charged drug solution,
iontophoresis repels ions of the drug, thus transporting them
across the skin or other membrane. In ear procedures, attempts have
been made in the past to use iontophoresis to anesthetize (or
"numb") a TM before placing an ear tube across it to treat chronic
ear infections. For TM iontophoresis, a drug solution is placed in
an ear canal and current is applied to the solution, thus
transporting the anesthetizing drug across the TM.
In theory, iontophoresis should be ideal for numbing a TM, because
it would allow drug to be transported across the full thickness of
the TM, would focus the drug delivery on the TM and the surrounding
ear canal, and would not require a painful injection with a needle.
Iontophoretic drug delivery to the TM has proven challenging,
however. Companies such as Xomed, Inc. (Medtronic Xomed, Inc.) and
Otomed, Inc. (Lake Havasu City, Ariz.) have previously provided
iontophoresis systems for anesthetizing TMs, but these systems and
their associated methods have had a number of significant
drawbacks. Most significantly, it has been very challenging, using
previous iontophoresis systems, to provide adequate anesthesia to
the TM without causing significant pain and discomfort to the
patient in the process. Although the pain and discomfort caused by
applying current to an iontophoretic solution in the ear canal may
range from mild to severe, even mild pain or discomfort may make an
ear tube placement procedure intolerable for pediatric patients and
even some adult patients.
To drive a drug solution across a TM via iontophoresis, the
solution must have certain characteristics to allow it to be
transported, and current must be applied in such a way to cause the
transport. Previously used iontophoresis solutions for TM
anesthesia were generally mixtures of Lidocaine and epinephrine,
often having a pH range of about 5.2-5.9, and this pH range was
thought to be optimal for ionophoretic drug delivery. Once the
solution is in place in the ear canal, a sufficient amount of
current must be applied for a sufficient amount of time to
transport the anesthetizing drug across the TM. Unfortunately, with
previously available systems, the combinations of drug solution and
current application were typically at least uncomfortable and often
quite painful. Attempts to decrease the pain caused by
iontophoresis generally resulted in unsatisfactory drug
delivery.
Placement of ear tubes through the TMs for treating chronic ear
infections is one of the most common ear, nose and throat ("ENT" or
"otolaryngology") surgical procedures requiring general anesthesia
in children. Although tube placement is a relatively routine
procedure, it almost always requires general anesthesia when
performed on children, since they are usually unable to tolerate
the pain and discomfort associated with numbing the tympanic
membranes for the procedure. Unfortunately, general anesthesia
carries a number of risks, some of which are still unknown and
being researched. Adult patients sometimes undergo ear tube
placement with topical applications of local anesthesia (such as
phenol), thus avoiding general anesthesia, but oftentimes such a
procedure is quite painful or at least very uncomfortable, due to
unsatisfactory methods of numbing the TMs. Therefore, it would be
highly advantageous to provide a method for anesthetizing TMs and
surrounding ear tissue that would eliminate the need for general
anesthesia and that would be palatable to patients.
Therefore, a need exists for improved iontophoretic methods and
systems. Ideally, such methods and systems would facilitate
iontophoretic drug delivery across a tympanic membrane for ear tube
placement or other surgical procedures in the ear. Also ideally,
such methods and systems would minimize or eliminate any pain
caused by the iontophoresis process. At least some of these
objectives will be met by the various embodiments of the present
invention.
BRIEF SUMMARY OF THE INVENTION
The present invention is directed to novel and advantageous
iontophoretic drug delivery methods and systems, which may be used
by ENT surgeons to anesthetize tympanic membranes (TMs). Various
embodiments include means for providing simultaneous bilateral
anesthetization of the TMs, reduction in patient discomfort via
control of applied current, current density and ramp rate,
allowance for intervention during the procedure by a physician,
enhanced and real-time monitoring of the output current, and/or
collection of the system's operational data.
In one embodiment, the present invention provides a method of
anesthetizing a tympanic membrane of an ear of a patient using
iontophoresis. The method may involve delivering an anesthetizing
drug solution to an ear canal of the patient's ear, wherein the
drug solution includes an anesthetic and a buffer, and wherein the
drug solution has a pH in the range of about 6.5 to about 7.5; and
applying an amount of current to the drug solution, wherein the
amount of applied current is increased at a rate of less than about
0.5 milliamp per minute until a maximum current is achieved.
In one aspect, the anesthetic may include Lidocaine and the buffer
may include sodium bicarbonate, and wherein the solution also
includes epinephrine. The drug solution may include approximately
2%-4% Lidocaine by weight. The drug solution may include
approximately 0.5%-1.0% sodium bicarbonate by weight.
In one aspect, the drug solution may have a pH range of about
6.8-7.2.
In another aspect, the application of the current may involve
increasing the amount of applied current at a rate of about 0.2
milliamp per minute.
In another aspect, the application of the current may involve
applying a maximum current of approximately 1.0 milliamp or less.
In another aspect, the application of the current may involve
applying a maximum current of approximately 0.8 milliamp or
less.
In another embodiment, the present invention provides a method of
anesthetizing a tympanic membrane of an ear of a patient using
iontophoresis. The method may involve adding buffer to an
anesthetizing drug solution for iontophoresis, wherein the drug
solution with added buffer has a pH in the range of about 6.5 to
about 7.5; delivering the buffered anesthetizing drug solution to
an ear canal of the patient's ear; and applying an amount of
current to the drug solution, wherein the amount of applied current
is increased at a rate of less than about 0.5 milliamp per minute
until a maximum current of less than about 0.5 milliamp is
achieved.
In one aspect, the buffered drug solution has a pH range of about
6.8-7.2.
In another aspect, the application of the current may involve
increasing the amount of applied current at a rate of about 0.2
milliamp per minute.
In another aspect, the application of the current may involve
applying a maximum current of approximately 0.8 milliamp or
less.
In another embodiment, the present invention provides a method of
treating a patient, the patient having a first and a second ear
canal. The method may involve positioning a fluid in the first ear
canal, the fluid comprising a therapeutic agent; positioning a
fluid in the second ear canal, the fluid comprising a therapeutic
agent; inserting a first electrode of an iontophoresis device in
the first ear canal; inserting a second electrode of the
iontophoresis device in the second ear canal; attaching one ground
electrode of the iontophoresis device to the patient, the first
electrode and the one ground electrode forming a first circuit, the
second electrode and the same one ground electrode forming a second
circuit; applying the agent from the fluid to a target tissue in
the first ear canal by energizing the first circuit to deliver a
current to the agent in the first ear canal; and applying the agent
from the fluid to a target tissue in the second ear canal by
energizing the second circuit to deliver a current to the agent in
the second ear canal, independently of the applying in the first
circuit.
In one aspect, the agent may include an anesthetic.
In another aspect, the agent may include at least one of lidocaine,
epinephrine, sodium bicarbonate, other anesthetics, other buffers,
or combinations thereof.
In another aspect, the agent may include at least one of an
antibiotic, an anti-inflammatory, a mucolytic, an anesthetic, a
steroid, an anti-viral, a surfactant or combinations thereof.
In another aspect, the energizing of the first or the second
circuit may include applying a current to the agent over a time
period, the current having an initial value, a final value, a
ramp-up rate from the initial value to the final value and a
ramp-down rate from the final value to the initial value. The
ramp-up rate is about 0.2 milliamp per minute. The ramp-up rate may
have a stepped and positive slope. The final value may be less than
about 1.0 milliamp. The period of time may be between about 30 and
240 seconds.
In another aspect, the method may also involve pausing the
application of the agent during the application.
In one aspect, the fluid is an iontophoretic solution of lidocaine
and epinephrine that is buffered to have a pH of about 6.8-7.2.
In another aspect, the iontophoretic solution may have a lidocaine
HCl concentration between approximately 2%-4% by weight.
In another aspect, the method may also include monitoring the first
or the second circuit's output current. In one aspect, the
monitoring may involve comparing the output current with a
threshold value. In another aspect, the monitoring may be performed
at a rate of at least once per second.
In another embodiment, the present invention provides an
iontophoresis system for anesthetizing a tympanic membrane of an
ear of a patient. The system may include an anesthetizing drug
solution including an anesthetic and a buffer and having a pH in
the range of about 6.5 to about 7.5; a current source; and a
controller coupled with the current source, the controller
programmed to increase an amount of current applied to the drug
solution at a rate of less than about 0.5 milliamp per minute until
a maximum current of less than about 1.0 milliamp is achieved.
In one aspect, the anesthetizing drug solution may include an
anesthetic, epinephrine and a buffer. The drug solution may have
approximately 2%-4% of Lidocaine by weight and approximately
0.5%-1.0% of sodium bicarbonate by weight.
In another aspect, the drug solution may have a pH range of about
6.8-7.2.
In another aspect, the controller may be programmed to increase the
amount of current applied to the drug solution at a rate of about
0.2 milliamp per minute until a maximum current of about 0.8
milliamp is achieved.
In another aspect, the current source may include at least one ear
electrode configured for placement in an ear canal of the
patient.
In another aspect, the current source may include two ear
electrodes configured for placement in two ear canals of the
patient, thus allowing for approximately simultaneous application
of current to anesthetizing drug solution disposed in the two ear
canals.
For further understanding of the nature and advantages of the
various embodiments, reference should be made to the following
description taken in conjunction with the accompanying figures.
Each of the figures is provided for the purpose of illustration and
description only and is not intended to limit the scope of the
embodiments of the present invention.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 illustrates an exemplary iontophoresis system, according to
one embodiment of the present invention.
FIG. 2 is an exemplary circuit diagram illustrating the electronic
architecture of the iontophoresis system of FIG. 1.
FIG. 3 illustrates exemplary sensometers that may be operatively
coupled with an iontophoresis system, according to one embodiment
of the present invention.
FIG. 4 illustrates an exemplary current ramp rate for an
iontophoresis system, according to one embodiment of the present
invention.
DETAILED DESCRIPTION OF THE INVENTION
According to various embodiments, an iontophoresis method and
system may provide ear, nose and throat ("ENT") surgeons (also
called "otolaryngologists") with an improved means for
anesthetizing tympanic membranes (TMs). An exemplary iontophoresis
system that may be enhanced using embodiments of the present
invention is described in the assignee's copending patent
application Ser. No. 11/749,729, entitled "Disposable Iontophoresis
System and Tympanic Membrane Pain Inhibition Method," which is
incorporated fully herein by reference. Certain aspects of that
system are described below.
FIGS. 1-2 are used to illustrate various aspects of an
iontophoresis system 300, according to one embodiment. As shown in
FIG. 1, iontophoresis system 300 may include a battery powered
disposable electronic device 310 having an LCD display 308 one or
more buttons 312 for operation, two electrodes (one for each ear)
302A-B couplable with device 310, and a return electrode patch 306
couplable with device 310. Device 310 may be configured to deliver
regulated current to electrodes 302A-B. Each electrode 302A-B may
be configured to fit within an external ear canal or a guide block
that is positioned in the ear canal. Each electrode 302A-B may be
configured to conform to the shape of a patient's ear canal and
thus retain a drug solution in the canal while delivering
electrical current to the solution. Various embodiments of
electrodes 302A-B may be sized to fit patients ranging in age from
12 months to adult. Return electrode 306 may be attached to the
patient's skin to complete the electrical circuit. As shown in FIG.
1, the iontophoresis system 300 may be a small electronic device,
in various embodiments ranging from about the size of a business
card to the size of an iPod.TM. or personal digital assistant. In
one embodiment, device 310 may be co-located with return electrode
patch 306 to minimize the amount of loose wires and overall package
size. In this embodiment, return electrode patch 306 may be
attached permanently or by means of a metal snap or other
electrically conductive attachment mechanism to device 310, and
device/patch 310/306 may be adhered to the patient's skin (e.g. at
the back of the neck) via return electrode patch 306, thereby
fixing the device 310 in a location easily accessible to the
physician but not easily accessible to the patient.
In one embodiment, iontophoresis system 300 may be activated by
pulling a small plastic tab (not shown) from the back of device
310. Such a tab may be configured to keep batteries installed in
device 310 from powering the device circuitry until desired. When
the tab is pulled, the batteries begin powering the circuitry and
the LCD 308 may illuminate. In alternative embodiments, any other
suitable means for powering device 310 may be included, such as a
power switch or button.
In various embodiments, device 310 may be powered before or after
applying return electrode 306 to the patient. At some point, a
solution is placed in the patient's ear canal, an electrode 302A-B
is placed in the canal, and electrode 302A-B is used to apply
current to the solution. In some embodiments, electrode 302A-B may
be placed in the canal before solution is placed, and the solution
may then be passed into the canal through or around electrode
302A-B, such as when a guide block is used. In some embodiments,
solution may be placed in one ear, an electrode 302A may be
positioned in that ear canal, solution may be placed in the other
ear, an electrode 302B may be placed in that ear, and then
iontophoresis may be performed on both ears simultaneously, almost
simultaneously, or sequentially. Alternatively, a left electrode
302A may be placed first, and a "Left Ear Start" button on device
310 may be pressed to begin an automatic, pre-programmed current
delivery sequence. A right ear electrode 302B may then be placed
into the patient's right ear canal and a "Right Ear Start" button
may be pressed to independently begin current delivery to the right
ear. In some embodiments, a progress meter may be displayed for
each ear on LCD 308. For example, a progress meter may be
represented by a filled-in area of a box, which starts empty and
fills in as current is delivered until is it fully filled and the
process is complete. Once current delivery starts, the user can
wait for the device to signal it is finished or there is a problem
via an auditory beep sound. After the device delivers the full
dosage of current to each ear, the progress meter for each ear is
filled and the system can deliver a short series of beeps to signal
successful completion. Once the device signals it is completed it
can automatically shut down. At this point, the user can remove the
electrodes, and can start the process of removing any iontophoresis
solution remaining in the ear canal. Again, this can be done
independently on one side without affecting proper device operation
on the other side.
At any time during the process, the current delivered to an
electrode can be paused, for example by pressing the left or right
button. The system can then ramp down the current to that
electrode. The user can also pause both electrodes at once, for
example by pressing the stop button. This will cause the system to
ramp down the current to both electrodes. In either case the user
can continue with the procedure by pressing the left or right
buttons. This will cause the system to ramp up the current for that
electrode and continue delivering the total charge where it left
off before being paused. In one embodiment, the same button may be
used for starting, pausing and stopping current delivery to an
electrode, while in alternative embodiments separate start, pause
and/or stop buttons may be included.
At the end of the iontophoresis current delivery cycle, the current
will ramp down to zero. Once both sides have completed
iontophoresis and the electrodes have been removed, the return
patch can also be removed and the entire unit discarded. Power can
automatically shut off after one hour of time, or any selected unit
of time. The unit can be designed to allow only one use and can not
be turned back on. Another embodiment disables the current delivery
function after a single use, but then enables additional
functionality, such as a game, a clock, etc. for the patient's use
after the procedure.
In some embodiments, if an error occurs during a procedure, the
system may emit an indicator signal, such as a series of long
beeps. Alternatively, or in addition to the series of long beeps,
visual means may be used, so as not to disturb the patient. For
example, a blinking light located on the back of the unit or other
hard to reach place would likely not be noticed by patient.
Conditions that could cause such an error include: a detected open
circuit or an over current condition. In the case of an open
circuit, the device may automatically stop delivering current to
the patient through a controlled current ramp down and the user may
resume delivery by pressing a start button on the device. In the
case of over current, the device may detect an internal error,
automatically stop all current to both electrodes, and not restart,
at which point the device may be discarded. In some embodiments, an
indicator message may be displayed on LCD screen 308.
Referring now to FIG. 2, a circuit diagram illustrating one
embodiment of an electronic architecture for iontophoresis system
300 is shown. In one embodiment, once the plastic tab is removed
from the back of device 310, two 3V batteries begin to power the
circuit. The batteries may supply a LP2975 voltage regulator, which
delivers a stable 5V output. The 5V output is used to supply the
microprocessor (e.g., Atmel ATtiny 261), the digital-to-analog
converter (DAC) converter (e.g., Maxim MCP4922), the current
sensing operational amplifiers (e.g., LM358), and all components of
the operator interface (buttons, buzzer, LCD). The microprocessor
controls the majority of the functions of the emergency stop button
to ramp down current to both electrodes; analog inputs for sensing
current delivered to each electrode; serial peripheral interface
(SPI) communications to set reference for the DAC; control signals
for buzzer and LCD. External to the microprocessor, the 6V battery
power drives the MAX5028 DC-DC converter which converts the battery
voltage to a 30V output. This output is used as the rail power for
the constant current unit. The constant current unit can be
designed using one of two alternatives. The first alternative uses
an Operational Amplifier (Op-Amp) such as LM358 which converts a
differential input voltage (the control signal) to an output
voltage, and eventually to a current based on the chosen sense
resistor. The second technique uses Operational Transconductance
Amplifiers (OTA) which operate in a manner similar to an Op-Amp in
that it is controlled by a differential input voltage, but it
drives an output current based on a biasing current provided
externally.
The microprocessor sets a reference voltage level to the current
source using a DAC. The microprocessor communicates to the DAC via
a serial protocol SPI. The constant current source uses a control
signal (0-5V) from the microprocessor to ramp 0 to 1 mA of current
according to a predetermined ramp shape. The DC-DC converter
provides a high enough rail voltage (30V) to allow the constant
current source to drive 1 mA of current based on a maximum expected
body resistance of 22.5 kOhms. After the allotted delivery time,
the microprocessor ramps the control signal back down to 0V, which
reduces the current delivered by the current source back to
zero.
The system may include an LM358 Op-Amp on each electrode line to
measure the current delivered to the patient. The Op-Amps are
connected to analog-to-digital converters internal to the
microprocessor. This gives feedback information to the
microprocessor for sensing of open circuits within the electrode
circuit and to calculate total charge delivered to the patient. For
safety, the current sensing Op-Amps in parallel with the output
electrode also drive an over current monitor. If a fault occurs and
current increases beyond a set limit of 1.5 mA due to some internal
failure, the transistor in the over current shunt will open and
allow the increased current to bypass the load, the patient in this
case, and safely return to the cathode (negative terminal) of the
battery. The microprocessor will independently detect the over
current condition, shut down the current source, and inform the
operator of a system fault.
After the system has completed delivering the total charge to the
patient it can go into a finished state and begin a timeout count.
At the end of the timeout count, the firmware may turn off the
system such that it cannot be turned back on. The microprocessor
may include EEPROM memory written to when the system is turned on
initially. If the system is re-powered, for instance, by forcibly
replacing the batteries, the firmware can detect that it has been
powered before and could not turn on again. This scheme is to
ensure the device is used only one time. The microprocessor
includes internal brown-out detection to detect if the system
voltage is below nominal This detection is used by the firmware to
disallow the system to begin or complete operation if the system
does not have enough power (e.g. if the batteries are drained).
As described above, the iontophoresis generator may provide two
independent channels of positive electrical current and a single
shared return electrode. Current may be ramped up to a set point
and maintained until sufficient charge has been delivered to the
drug solution. The current may then be ramped down, and the system
may inform the physician that current delivery is complete. In
various embodiments, the physician may stop or pause the procedure
at any time. In some embodiments, the physician may stop the
procedure immediately (i.e., without ramping down current delivery)
by simply removing the electrode from the ear canal.
Thus, in some embodiments, the iontophoresis system has two
independent channels, each with its own ear electrode and sharing a
single common return electrode. This allows each TM to be
anesthetized independently but also at the same time, decreasing
the amount of time required for the procedure. The simultaneous
bilateral delivery of iontophoresis can cut the procedure time
roughly in half when compared with how the existing devices are
used. This is especially useful in reducing the time children are
asked to sit still and tolerate devices in their ears.
Referring now to FIG. 4, in some embodiments, current ramp rate of
an iontophoresis method may be configured to minimize or eliminate
patient pain and discomfort while still providing sufficient
current to transport a drug solution across a TM within a desired
amount of time. In some embodiments, an iontophoresis method may
involve a slower current "ramp rate" (rate at which the amount of
delivered current is increased) and thus a longer current ramp-up
period. In some embodiments, for example, delivered current may
increase from zero at a rate of less than about 0.5 mA/min and even
more ideally at a rate of about 0.2 mA/min In some embodiments,
total ramp-up time (from zero current delivered to maximum current
delivered) may be from about 2 minutes to about 5 minutes and even
more ideally from about 3 minutes to about 4 minutes. Maximum
current delivered may vary according to various embodiments, for
example in some embodiments it may range from about 0.5 mA to about
1.0 mA and even more preferably between about 0.7 mA and about 0.9
mA and even more preferably about 0.8 mA. The maximum current may
be maintained for any suitable desired amount of time to achieve TM
anesthesia, such as from less than one minute to over ten minutes
and in some embodiments for example from about five minutes to
about eight minutes. Any suitable ramp-down time for the current
may be used at the end of iontophoretic current delivery, such as
in one embodiment from less than one minute to about two minutes.
In one embodiment, a total time for iontophoresis of one TM may
take between about five minutes and about fifteen minutes and even
more preferably between about seven minutes and about twelve
minutes.
In some embodiments, a drug solution provided for TM iontophoresis
may be configured to minimize or eliminate pain and discomfort.
Because it has been found that iontophoresis current delivered
through an acidic iontophoresis solution may be more painful than
current delivered through a more neutral solution, in some
embodiments a solution with a more neutral pH may be provided. In
one embodiment, for example, a buffer may be added to a
conventional iontophoresis solution of Lidocaine and epinenphrine.
Examples of buffers that may be used include but are not limited to
sodium bicarbonate. For example, some previously used iontophoresis
solutions may have included Lidocaine (4%) and Epinephrine
(1:1000), with a pH in the range between 5.2-5.9. Epinephrine is
packaged in an acidic solution (e.g., .about.3.0 pH) to extend its
shelf life, but it is stable at higher pH levels for the duration
of time that iontophoresis takes place. Therefore, in one
embodiment, just prior to use, an iontophoresis solution may be
buffered to a neutral pH with sodium bicarbonate or some other
buffer.
In some embodiments, where a buffer is included in an iontophoresis
solution, the solution may also include a higher Lidocaine
concentration than in previously used solutions. Since a buffer may
slow the rate at which the solution is driven across the TM,
increasing the Lidocaine concentration may make up for this slowing
by increasing the percentage of ionized lidocaine molecules in the
buffered iontophoresis solution. For example, an unadjusted
iontophoresis solution may comprises a solution of 1:2000
epinephrine and 2% Lidocaine HCl, having a pH between approximately
5.2-5.9. When the solution is buffered to a neutral pH of about 7,
the degree of ionization of Lidocaine will decrease. Since
iontophoresis uses electrical current to push ionized molecules
across a biological membrane such as the TM, the buffering will
cause a decrease in Lidocaine flux due to the increased pH. One way
to balance this decrease in iontophoresis transport is to increase
the amount of ionized molecules in the starting solution by
increasing the concentration of Lidocaine. For example, if the
iontophoretic solution started with a 3.3% lidocaine HCl
concentration instead of 2%, then even a loss of 20% of the ionized
molecules by raising the pH to 7, will result in a solution having
a 2.6% lidocaine HCl concentration. Accordingly, in various
embodiments, the solution may have up to 4% lidocaine HCl, as this
amount has been determined to be safe for iontophoretic purposes.
In some embodiments, the amount of epinephrine in solution may also
be adjusted.
In one embodiment, an iontophoresis system may be configured to
deliver a maximum output per channel of about 30 volts. In one
embodiment, an iontophoresis system may be configured to monitor
the actual current output and calculate the charge delivered. In
one embodiment, output current may be monitored in a fault-tolerant
manner. For this, the output current may be compared to the
intended current several times a second. Then when the measured
output current is outside of the allowable range, a "strike" is
recorded. If a certain number of strikes accumulates within a block
of time, the user may be alerted that the system needs to be
checked.
In one embodiment of an iontophoresis method, the current being
delivered to each channel may be ramped up in steps, such that the
current set point is raised to a value, maintained for a certain
amount of time, and then raised again. This method of ramping the
current up or down may help facilitate current monitoring. In
another embodiment, output of the iontophoresis device may be
recorded. For example, output voltage, output current, and/or
setpoint current of each channel may be sent to a data acquisition
system and recorded over the course of the procedure, without
interfering with the current supplied to the patient. In one
embodiment, from this data, changes in body resistance and power
output may be calculated.
In one embodiment, an iontophoresis system may further be
configured to record patient discomfort continuously over the
course of the procedure using a sensometer as shown in FIG. 3. As
shown in FIG. 3, the patient can adjust a dial 402 or slider 404,
which can correspond to a pain level. The scale can use a numeric
range as in dial 402 or a more user friendly scale that shows a
face pain scale may be used. The dial or slider is attached to a
potentiometer such that the output voltage or current is correlated
with a pain level. Patient discomfort could be compared second by
second with the electrical output to better inform subsequent
current delivery settings to reduce patient discomfort. The
sensometer can be operatively connected with the iontophoresis
generator. The iontophoresis generator could then monitor the
patient's level of discomfort and adjust the output accordingly,
such as temporarily reducing output current until the patient felt
better. The data may be recorded alongside the output of the
iontophoresis machine.
The present invention may be embodied in other specific forms
without departing from the essential characteristics thereof. These
other embodiments are intended to be included within the scope of
the present invention, which is set forth in the following
claims.
* * * * *
References